Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.
Theodor UdenAlice BertainaJonas AbrahamssonMarc AnsariAdriana BalduzziJean-Pierre BourquinCorinne GerhardtMarc B BieringsHenrik HasleArjan LankesterKirsten MischkeAndrew S MooreIan Nivison-SmithAnna PieczonkaChristina PetersPetr SedlacekDirk ReinhardtJerry SteinBirgitta VersluysJacek WachowiakLeen WillemsMartin ZimmermannFranco LocatelliMartin G SauerPublished in: British journal of haematology (2020)
Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four-year probability of overall survival (4y-pOS) was 14%. 4y-pOS for 122 children receiving a second haematopoietic stem cell transplantation was 31% and 3% for those that did not (P = <0·0001). Achievement of a subsequent remission impacted survival (P = <0·0001). For patients receiving a second transplant survival with or without achieving a subsequent remission was comparable. Graft source (bone marrow vs. peripheral blood stem cells, P = 0·046) and donor choice (matched family vs. matched unrelated donor, P = 0·029) positively impacted survival after relapse. Disease recurrence and non-relapse mortality at four years reached 45% and 22%.
Keyphrases
- stem cell transplantation
- free survival
- high dose
- bone marrow
- stem cells
- multiple sclerosis
- young adults
- disease activity
- peripheral blood
- acute myeloid leukemia
- mesenchymal stem cells
- low dose
- systemic lupus erythematosus
- type diabetes
- rheumatoid arthritis
- risk factors
- cardiovascular events
- ulcerative colitis
- cell therapy
- hepatitis b virus